Along with the rest of the market, Novo Nordisk (NYSE:NVO) has been sinking this year – with losses approaching 30% ...

But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Novo Nordisk's booming obesity drugs & diabetes portfolio make it a top growth play. Click here to read an analysis of NVO ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Novo Nordisk, the Danish maker of Ozempic and Wegovy, announced Tuesday that it has asked the Food and Drug Administration to ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of ...

Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The South Korean office of the Danish pharmaceutical company Novo Nordisk recently requested the local authorities to permit ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...